Maria Koehler: Real-world data is “truly a revolution”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong

YOU MAY BE INTERESTED IN

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login